Insulin resistance, dyslipidemia, and cardiovascular disease

Diabetes Care

Volumn 30, Issue 8, 2007, Pages 2164-2170

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PROTEIN KINASE C; PROTEIN P110; RETINOID X RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FAT INTAKE; FATTY ACID TRANSPORT; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PHENOTYPE; PROTEIN INTAKE; THROMBOSIS; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; GENOTYPE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS;

EID: 34547670932     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-zb08     Document Type: Note

References (44)

1. Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363-1379, 2002
2. Krauss RM, Dreon DM: Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men. Am J Clin Nutr 62:478S-487S, 1995
3. Krauss RM: Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol 25:2265-2272, 2005
4. Krauss RM: Dietary and genetic effects on low-density lipoprotein heterogeneity. Annu Rev Nutr 21:283-295, 2001
5. Dreon DM, Fernstrom HA, Williams PT, Krauss RM: Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns. Am J Clin Nutr 71:1611-1616, 2000
6. Corella D, Qi L, Sorli JV, Godoy D, Portoles O, Coltell O, Greenberg AS, Ordovas JM: Obese subjects carrying the 11482G>A polymorphism at the perilipin locus are resistant to weight loss after dietary energy restriction. J Clin Endocrinol Metab 90:5121-5126, 2005
7. Glass CK: Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116:556-560, 2006
8. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, Plutzky J: Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 100:2730-2735, 2003
9. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J: High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res 98:490-498, 2006
10. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr: Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 113:2914-2918, 2006
11. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129-1134, 2002
12. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM: Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 286:1468-1474, 2001
13. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospectivestudy. Lancet 359:2140-2144, 2002
14. Matz K, Keresztes K, Tatschl C, Nowotny M, Dachenhausenm A, Brainin M, Tuomilehto J: Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. Diabetes Care 29:792-797, 2006
15. Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR Jr, Ludwig DS: Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 365:36-42, 2005
16. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Buzzigoli E, Ghione S, Turchi S, Lombardi M, Ferrannini E: Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 44:127-133, 2004
17. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronicrenal failure. Lancet 339:572-575, 1992
18. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23:1455-1459, 2003
19. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420-1426, 2002
20. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, Wolzt M, Kautzky-Willer A: Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia 45:1372-1378, 2002
21. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106:987-992, 2002
22. Dunn EJ, Philippou H, Ariens RA, Grant PJ: Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071-1080, 2006
23. Goldfine AB, Beckman JA, Betensky RA, Devlin H, Hurley S, Varo N, Schonbeck U, Patti ME, Creager MA: Family history of diabetes is a major determinant of endothelial function. J Am Coll Cardiol 47:2456-2461, 2006
24. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW, Hsueh WA, Schelbert HR: Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 111:2291-2298, 2005
25. Mehta JL, Hu B, Chen J, Li D: Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 23:2203-2208, 2003
26. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23:729-736, 2003
27. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111:2525-2531, 2005
28. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106:2055-2060, 2002
29. Marfella R, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, Crescenzi B, Cirillo F, Nicoletti GF, D'Andrea F, Chiorazzo G, Musacchio E, Rossi F, Verza M, Coppola L, D'Amico M: The vascular smooth muscle cells apoptosis in asymptomatic diabetic carotid plaques: role of glycemic control. J Am Coll Cardiol 47:2118-2120, 2006
30. Bressler P, Bailey SR, Matsuda M, De-Fronzo RA: Insulin resistance and coronary artery disease. Diabetologia 39:1345-1350, 1996
31. Goff DC Jr, Zaccaro DJ, Haffner SM, Saad MF, the Insulin Resistance Atherosclerosis Study: Insulin sensitivity and the risk of incident hypertension: insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 26:805-809, 2003
32. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
33. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112:3066-3072, 2005
34. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83:2773-2776, 1998
35. Hanley AJ, Williams K, Stern MP, Haffner SM: Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25:1177-1184, 2002
36. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the bruneck study. Diabetes Care 30:318-324, 2007
37. Israeli Society for Prevention of Heart Attacks: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21-27, 2000
38. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, Collins D, the Veterans Affairs HDL Intervention Trial (VA-HIT): Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26:1513-1517, 2003
39. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators: Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861, 2005
40. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of Diabetes in Obese Subjects (XENDOS) Study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155-161, 2004
41. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478, 2004
42. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105, 2006
43. DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551-1562, 2006
44. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368:581-588, 2006